TGF-β is a multifunctional signalling protein that is involved in cell growth, wound healing, and immune response. Therefore, in many diseases such as cancer, fibrosis, and pulmonary fibrosis, TGF-β is the ideal target for therapies. However, the pleotropic nature of TGF-β means that unspecific targeting, toxic side effects, and lack of clinical efficacy have hindered the development of TGF-β targeted therapies. The field has advanced but no TGF-β targeted therapies have been approved, due to the challenges faced by the double-edged sword nature of TGF-β.

Are you looking to partner with industry leading TGF-β-focused companies to support them in the development of safe and efficacious TGF-β targeted therapies?

The 4^th TGF-β Targeted Drug Development Summit brings together industry trailblazers in different stages of development, whether it is discovery, translation, or clinical. This is your opportunity to meet big names in the industry such as Cue Biopharma, EpicentRx, Morphic, and Pfizer, and begin a collaborative partnership with them.